17162 Pediatric Survivors after HCT: Long-term screening and preventive practices 2017-2018

Following hematopoietic cell transplantation (HCT), pediatric recipients face a high incidence of late effects, underscoring the need for long-term monitoring and early detection.1 To optimize the long-term care for patients with malignant and non-malignant diseases, this case-based activity explores post-autologous and allogeneic HCT screening recommendations, including: risk factors associated with exposures and late effects, screening and assessment guidelines, and vaccination schedules.

 

 

ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and National Marrow Donor Program. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Enduring material for a maximum of 1  AMA PRA Category 1 Credit(s) ™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1 hours of participation for continuing education for allied health professionals.  
 
 
For more information: Click here 

Target Audience

This activity is intended for pediatric hematologists,/oncologists, pediatricians, nurses, and other health care practitioners who care for pediatric patients following HCT.

Learning Objectives

At the conclusion of this activity, I will be able to:

  1. Identify the most common late effects experienced by pediatric HCT recipients that require ongoing follow up and care.
  2. Apply appropriate screening, testing and vaccination schedules from recommended guidelines according to each patient's exposures and risk factors.
  3. Utilize care planning tools as part of a patient's multidisciplinary team of care providers to identify, document and communicate needs for follow-up care.
Additional information

Contact

Name: 
Ellyce Hayes
Phone Number: 
+1 (612) 460-4231
Email: 
ehayes2@nmdp.org
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
03/14/2017
Course expires: 
03/14/2018
Cost:
$0.00
Planning Committee:
Mary Horowitz, MD
Angela Smith, MD, MS
Navneet Majhail, MD, MS
 
Faculty:

Angela Smith, M.D., M.S.  
Attending Physician, University of Minnesota Children's Hospital, Pediatric Blood and Marrow Transplantation, Minneapolis, MN 
Assistant Professor of Pediatrics, Hematology/ Oncology, and Blood and Marrow Transplantation, University of Minnesota

Navneet Majhail, M.D., M.S. 
Director, Bone Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 
Professor of Medicine, Department of Hematology & Oncology, Cleveland Clinic Lerner College of Medicine 
Scientific Director, Center for International Blood and Marrow Transplant Research (CIBMTR), Minneapolis, MN

All persons in control of content have NO relevant financial relationships to disclose except the following person(s):
 
NameCompanyRole
Nanveet Majhail, MD, MSAnthem, Inc.Committee Member
   

 

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.